Raghubar Arti M, Matigian Nicholas A, Crawford Joanna, Francis Leo, Ellis Robert, Healy Helen G, Kassianos Andrew J, Ng Monica S Y, Roberts Matthew J, Wood Simon, Mallett Andrew J
Kidney Health Service, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia.
NPJ Precis Oncol. 2023 Sep 11;7(1):88. doi: 10.1038/s41698-023-00441-5.
Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cell renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient outcomes. These unsuccessful ICI trials suggest that the tumour infiltrating immunophenotypes, termed here as the immune cell types, states and their spatial location within the tumour microenvironment (TME), were unfavourable for ICI treatment. Defining the tumour infiltrating immune cells may assist with the identification of predictive immunophenotypes within the TME that are favourable for ICI treatment. To define the immunophenotypes within the ccRCC TME, fresh para-tumour (pTME, n = 2), low-grade (LG, n = 4, G1-G2) and high-grade (HG, n = 4, G3-G4) tissue samples from six patients with ccRCC presenting at a tertiary referral hospital underwent spatial transcriptomics sequencing (ST-seq). Within the generated ST-seq datasets, immune cell types and states, termed here as exhausted/pro-tumour state or non-exhausted/anti-tumour state, were identified using multiple publicly available single-cell RNA and T-cell receptor sequencing datasets as references. HG TMEs revealed abundant exhausted/pro-tumour immune cells with no consistent increase in expression of PD-1, PD-L1 and CTLA4 checkpoints and angiogenic genes. Additional HG TME immunophenotype characteristics included: pro-tumour tissue-resident monocytes with consistently increased expression of HAVCR2 and LAG3 checkpoints; an exhausted CD8 T cells sub-population with stem-like progenitor gene expression; and pro-tumour tumour-associated macrophages and monocytes within the recurrent TME with the expression of TREM2. Whilst limited by a modest sample size, this study represents the largest ST-seq dataset on human ccRCC. Our study reveals that high-risk ccRCC TMEs are infiltrated by exhausted/pro-tumour immunophenotypes lacking specific checkpoint gene expression confirming that HG ccRCC TME are immunogenic but not ICI favourable.
针对中高危透明细胞肾细胞癌(ccRCC)的围手术期免疫检查点抑制剂(ICI)试验未能始终如一地证明能改善患者预后。这些失败的ICI试验表明,肿瘤浸润免疫表型,在此称为免疫细胞类型、状态及其在肿瘤微环境(TME)中的空间位置,对ICI治疗不利。定义肿瘤浸润免疫细胞可能有助于识别TME中有利于ICI治疗的预测性免疫表型。为了定义ccRCC TME中的免疫表型,对一家三级转诊医院收治的6例ccRCC患者的新鲜瘤旁组织(pTME,n = 2)、低级别(LG,n = 4,G1 - G2)和高级别(HG,n = 4,G3 - G4)组织样本进行了空间转录组测序(ST-seq)。在生成的ST-seq数据集中,以多个公开可用的单细胞RNA和T细胞受体测序数据集为参考,识别出免疫细胞类型和状态,在此称为耗竭/促肿瘤状态或非耗竭/抗肿瘤状态。HG TME显示出丰富的耗竭/促肿瘤免疫细胞,PD-1、PD-L1和CTLA4检查点以及血管生成基因的表达没有持续增加。HG TME的其他免疫表型特征包括:促肿瘤组织驻留单核细胞,HAVCR2和LAG3检查点的表达持续增加;具有干细胞样祖基因表达的耗竭CD8 T细胞亚群;以及复发TME中具有TREM2表达的促肿瘤肿瘤相关巨噬细胞和单核细胞。尽管受样本量较小的限制,但本研究代表了关于人类ccRCC的最大ST-seq数据集。我们的研究表明,高危ccRCC TME被缺乏特定检查点基因表达的耗竭/促肿瘤免疫表型浸润,证实HG ccRCC TME具有免疫原性,但对ICI治疗不利。